On DCA for prediction of ≥ pT3 disease, lymph node metastasis and any NOCD, only the addition of pretreatment plasma levels of IL6 to the previously described reference model resulted in a slight improvement of the clinical net benefit for prediction of lymph node metastasis, ≥ pT3 disease and any NOCD (Fig. 1). The gene discussed is IL6; the disease is metastatic malignant neoplasm in the lymph nodes.